JPM15: Abbott Eyes Emerging Markets Only For Branded Generics Biz
This article was originally published in PharmAsia News
Executive Summary
Just in case the sight of Abbott divesting its branded generics businesses in developed markets to Mylan was not a clear enough signal of the company’s intention to focus solely on emerging markets, Michael J. Warmuth , the EVP with responsibility for the business, took the opportunity to spell it out at the recent JP Morgan Healthcare conference.